Vertex Pharma (VRTX) operating income was $4.2B in FY2025 (+1892% YoY). The tables below show the complete quarterly and annual operating income history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Operating Income
Fiscal Year
Operating Income
YoY
2025
$4.2B
+1892%
2024
-$233M
-106%
2023
$3.8B
-11%
2022
$4.3B
+55%
2021
$2.8B
-3%
2020
$2.9B
+139%
2019
$1.2B
+89%
2018
$635M
+362%
2017
$137M
+1128%
2016
$11M
+102%
2015
-$465M
+28%
2014
-$641M
-13%
2013
-$569M
-1272%
2012
$49M
-58%
2011
$116M
+117%
2010
-$695M
-14%
2009
-$608M
-33%
2008
-$458M
Recent Quarterly Operating Income
Quarter
Operating Income
Q1 2026
$1.1B
Q4 2025
$1.2B
Q3 2025
$1.2B
Q2 2025
$1.2B
Q1 2025
$630M
Q4 2024
$1.0B
Q3 2024
$1.1B
Q2 2024
-$3.5B
Q1 2024
$1.1B
Q4 2023
$988M
Q3 2023
$1.0B
Q2 2023
$1.0B
Source: VRTX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.